Market Opportunity:

By enabling the precise engineering of any cell type within the human body, ImmunoVec is opening a new era of programmable medicine. With unprecedented cell type-specific precision, ImmunoVec has the potential to unlock transformative treatments for autoimmune disease, solid tumors, and genetic disorders, advancing therapies once thought to be beyond reach.

Technology:

Our platform combines genetic control elements that enable fine-tuned, cell type-specific expression of therapeutic payloads across any delivery vehicle, viral or non-viral, for precise engineering of any desired cell types. Within our pipeline, we are accelerating the development of novel non-viral polymeric nanoparticles for precise in vivo immune cell engineering.

Advantages:

• Cell type specific expression
• Precision cellular engineering
• In vivo
• Non-viral
• Low-cost

Development Stage:

• Pre-Clinical

Patents Issued:

• Coming Soon

Select Publications:

• https://www.fiercebiotech.com/biotech/arpa-h-reveals-biotech-winners-vivo-cell-therapy-funding-sweepstakes
• https://www.prnewswire.com/news-releases/immunovec-launches-from-stealth-with-up-to-40-7-million-arpa-h-embody-award-to-advance-in-vivo-cell-engineering-platform-for-autoimmune-diseases-302578080.html
• https://www.precisionmedicineonline.com/precision-oncology/immunovec-tessera-therapeutics-latest-win-grants-under-arpa-h-gene-cell-therapy

Contact:

Website: www.immunovec.com

Email: info@immunovec.com

LinkedIn: linkedin.com/company/immunovec